Beam Therapeutics (BEAM) said Thursday the US Food and Drug Administration cleared its investigational new drug application for BEAM-302 to treat alpha-1 antitrypsin deficiency, an genetic disorder that affects lungs or liver.
Earlier this month, Beam disclosed initial safety and efficacy data from a global phase 1/2 study, showcasing the "first ever" clinical genetic correction of a disease-causing mutation, Giuseppe Ciaramella, president of Beam, said late Thursday.
The company plans to continue the dose-escalation portion of part A of the trial, including enrolling and dosing a fourth cohort. It expects to report further data during H2. In addition, it plans to dose the first patient in Part B, including AATD patients with mild-to-moderate liver disease in H2.
In addition to the US, the investigational formulation has received clinical trial authorization in the UK, New Zealand, Australia, the Netherlands, and Ireland.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.